Skip survey header

Molecular Testing: NSCLC Panel Pre-Test

The Emerging Role of Molecular Testing in an Era of Precision Medicine – Non-Small Cell Lung Cancer Cancer

A continuing education activity for physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists.

This activity is supported by an educational grant from AstraZeneca

Release date: October 19, 2017                        
Expiration date: October 19, 2018
Estimated time to complete activity: 1.0 hours


Patrick Kiel, PharmD (Moderator)
Indiana University, Indianapolis, IN

Gregory Durm, MD
Indiana University, Indianapolis, IN

Anna Livers-Ertel, ANP-BC, MSN, OCN
Franciscan Health, Indianapolis, IN

Activity Rationale and Purpose
A rapidly emerging concept that holds the promise of altering the natural history and subsequently outcomes for cancer patients is that of precision—or personalized—medicine. Precision medicine seeks to select the most effective treatment option for each individual patient’s tumor, given at the appropriate time in the life cycle of the disease predicated upon an understanding of the specific molecular nature of the tumor with the ultimate goal of improving survival and quality of life (QoL). There is an immediate and growing need to alert advanced practitioners about the role molecular profiling has in the treatment of non-small cell lung cancer, from a primarily prognostic to one that can also provide predictive guidance regarding the choice of a specific therapy.

Intended Audience
The intended audience for this enduring internet activity is physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists who specialize in the field of oncology.

Learning Objectives
After completing this educational activity, participants should be able to:
• Recognize the differences between prognostic and predictive genomic markers in practice, and the types of cancer in which indicative markers are currently being used in practice.
• Relate NCCN guideline recommendations regarding molecular testing in advanced NSCLC, including monitoring for acquired resistance with T790m, and the advantages and potential limitations of findings to treatment planning.
• Describe the appropriate molecular tests for patients with NSCLC.

Continuing Education


The Annenberg Center for Health Sciences at Eisenhower has been awarded Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME®)

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

A maximum of 1.0 contact hours may be earned for successful completion of this activity.


This knowledge-based accredited education lecture is intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Annenberg Center for Health Sciences at Eisenhower.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program # 0797-9999-17-091-H01-P. This program is designated for up to 1.0 contact hours (0.10 CEUs) of continuing pharmacy educational credit.

Financial Disclosures
All individuals in positions to control the content of this activity (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

Dr. Keil has served on speakers’ bureaus for Celgene, Gilead, and Takeda.
Dr. Durm has received research funding from Bristol-Myers Squibb and Merck.
Ms. Livers-Ertel has served on a speakers’ bureau for Celgene.

Lead Nurse Planner
Dorothy Caputo, MA, BSN, RN, has nothing to disclose.

Chris Cherry has nothing to disclose.
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CS, ANP, has nothing to disclose.
Lynn Rubin has nothing to disclose.
Annie Yueh has nothing to disclose.

Content Reviews
Elizabeth Gilbert, MS, PA-C, has nothing to disclose.

Annenberg Center for Health Sciences at Eisenhower
John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc.; Charles Willis, Director, Continuing Education, consults for Pfizer Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of the Annenberg Center for Health Sciences, Harborside Medical Education, and JADPRO for all educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Harborside Medical Education of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

How to Earn Credit
To claim credit for this activity, participants must complete the pre-assessment, view the content, pass the post-assessment, and complete and submit an evaluation. Content is available on

Statement of Credit: Participants who successfully complete this activity (including scoring 70% on the learning assessment and complete and submit the evaluation form) will be able to download a statement of credit.